Vilya
Vilya uses AI-driven computational design to generate novel macrocycle drugs for human diseases. Its medicines are designed to combine the target precision of biologics with the convenience of oral dosing, including for diseases that are difficult to treat with existing drugs.
Facts
- HQ
- Seattle, Washington, USA
- Sectors
- Biotechnology, Drug discovery, Artificial intelligence
- Founders
- David Baker, Gaurav Bhardwaj, Lance Stewart, Patrick Salveson, Adam Moyer, Nao Hiranuma
Is this your organization? Claim it
Helion Breaks Ground on Fusion Plant; Microsoft Reports $75 Billion Azure Revenue and Beats Expectations; Seattle Startups Highlighted
Helion Energy has begun construction on a potential first commercial fusion power plant, while Microsoft revealed its Azure annual revenue of $75 billion and beat earnings expectations in the June quarter. Additionally, Seattle’s tech and startup scene is highlighted by AI company growth and Flyhomes securing $15 million to pivot its real estate business.
Madrona, Point72 and Madrona Venture Labs make day-one investment in Tektonic to build GenAI agents for sales and revenue operations
Madrona announces a day-one investment in Tektonic alongside Point72 and Madrona Venture Labs; Tektonic builds GenAI agents to automate business operations, initially targeting sales and revenue tasks like quoting, renewals, services, and data quality.
Vilya Secures $71 Million Series A Funding Led by NVIDIA, ARCH, Madrona, and Menlo Ventures for AI-Driven Macrocyclic Drug Development
Vilya, a biotech startup developing macrocyclic drugs using AI and machine learning, announced an expanded $71 million Series A funding round led by ARCH Venture Partners, NVIDIA's NVentures, Madrona, and Menlo Ventures. The company, a spinout from Seattle's Institute for Protein Design, aims to revolutionize drug discovery with advanced protein engineering technologies.
See all 5 news stories about Vilya.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events